EA202090617A1 - Варианты антител - Google Patents

Варианты антител

Info

Publication number
EA202090617A1
EA202090617A1 EA202090617A EA202090617A EA202090617A1 EA 202090617 A1 EA202090617 A1 EA 202090617A1 EA 202090617 A EA202090617 A EA 202090617A EA 202090617 A EA202090617 A EA 202090617A EA 202090617 A1 EA202090617 A1 EA 202090617A1
Authority
EA
Eurasian Patent Office
Prior art keywords
antibodies
options
antibody
present
antibody options
Prior art date
Application number
EA202090617A
Other languages
English (en)
Inventor
Эстер Мария Фуррер
Original Assignee
Тиллоттс Фарма АГ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59923275&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA202090617(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Тиллоттс Фарма АГ filed Critical Тиллоттс Фарма АГ
Publication of EA202090617A1 publication Critical patent/EA202090617A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Настоящее изобретение относится к антителам, которые связываются с ФНО- и демонстрируют модифицированное связывание FcRn. Антитела согласно настоящему изобретению обладают хорошими эффекторными функциями и/или фармакокинетическими свойствами.
EA202090617A 2017-09-19 2018-09-11 Варианты антител EA202090617A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17191989.7A EP3456738A1 (en) 2017-09-19 2017-09-19 Antibody variants
PCT/EP2018/074522 WO2019057564A1 (en) 2017-09-19 2018-09-11 ANTIBODY VARIANTS

Publications (1)

Publication Number Publication Date
EA202090617A1 true EA202090617A1 (ru) 2020-07-27

Family

ID=59923275

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202090617A EA202090617A1 (ru) 2017-09-19 2018-09-11 Варианты антител

Country Status (21)

Country Link
EP (2) EP3456738A1 (ru)
JP (2) JP7240385B2 (ru)
KR (1) KR20200053514A (ru)
CN (1) CN111094343A (ru)
AR (1) AR113303A1 (ru)
AU (1) AU2018337495A1 (ru)
BR (1) BR112020005482A2 (ru)
CA (1) CA3075959A1 (ru)
CL (1) CL2020000721A1 (ru)
CO (1) CO2020003260A2 (ru)
CR (2) CR20200132A (ru)
EA (1) EA202090617A1 (ru)
GE (1) GEP20237484B (ru)
IL (1) IL273351A (ru)
JO (1) JOP20200063A1 (ru)
MA (1) MA50156A (ru)
MX (1) MX2020002989A (ru)
PH (1) PH12020500473A1 (ru)
SG (1) SG11202002220TA (ru)
TW (1) TW201915021A (ru)
WO (1) WO2019057564A1 (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019001458A (es) 2016-08-02 2019-07-04 Visterra Inc Polipeptidos modificados y usos de los mismos.
WO2020114616A1 (en) 2018-12-07 2020-06-11 Tillotts Pharma Ag Topical treatment of immune checkpoint inhibitor induced diarrhoea, colitis or enterocolitis using antibodies and fragments thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2348051T3 (en) * 2003-11-05 2019-03-18 Roche Glycart Ag CD20 antibodies with increased fc receptor binding affinity and effector function
CA2595112A1 (en) 2004-12-31 2006-07-13 Genentech, Inc. Polypeptides that bind br3 and uses thereof
CA3086659A1 (en) 2007-12-26 2009-07-09 Xencor, Inc. Fc variants with altered binding to fcrn
CN107936117B (zh) 2008-06-25 2022-12-23 诺华股份有限公司 抑制TNFα的稳定和可溶的抗体
WO2015158867A1 (en) 2014-04-16 2015-10-22 Ucb Biopharma Sprl Multimeric fc proteins
CR20180365A (es) 2015-12-16 2018-09-28 Amgen Inc PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS
US11319383B2 (en) * 2016-03-14 2022-05-03 Universitetet | Oslo Engineered immunoglobulins with altered FcRn binding

Also Published As

Publication number Publication date
IL273351A (en) 2020-05-31
EP3456738A1 (en) 2019-03-20
SG11202002220TA (en) 2020-04-29
GEP20237484B (en) 2023-03-27
US20200216527A1 (en) 2020-07-09
PH12020500473A1 (en) 2021-01-25
JP7402304B2 (ja) 2023-12-20
CR20200132A (es) 2020-07-24
JP2020534307A (ja) 2020-11-26
CL2020000721A1 (es) 2020-08-07
BR112020005482A2 (pt) 2020-09-29
CO2020003260A2 (es) 2020-04-13
CN111094343A (zh) 2020-05-01
AU2018337495A1 (en) 2020-04-09
WO2019057564A1 (en) 2019-03-28
JP7240385B2 (ja) 2023-03-15
KR20200053514A (ko) 2020-05-18
TW201915021A (zh) 2019-04-16
AR113303A1 (es) 2020-04-08
JOP20200063A1 (ar) 2020-03-17
CA3075959A1 (en) 2019-03-28
EP3684807A1 (en) 2020-07-29
JP2023036885A (ja) 2023-03-14
CR20210205A (es) 2021-07-27
MA50156A (fr) 2020-07-29
MX2020002989A (es) 2020-07-22

Similar Documents

Publication Publication Date Title
EA201891582A1 (ru) Иммуностимулирующие гуманизированные моноклональные антитела против интерлейкина-2 человека и их слитые белки
PH12018501778A1 (en) Antibodies to tigit
EA201792467A1 (ru) Гетеродимерные антитела, которые связывают cd3 и опухолевые антигены
EA201890790A1 (ru) Связывающие pd-1 белки и способы их применения
EA202092847A1 (ru) Антитела к cd3 и их применение
PH12018502225A1 (en) Anti-il-33 antibodies, compositions, methods and uses thereof
EA201791139A1 (ru) Гетеродимерные антитела, которые связывают cd3 и опухолевые антигены
EA201791164A1 (ru) Гетеродимерные антитела, связывающие cd3 и cd38
MX2019012953A (es) Anticuerpo biespecifico contra ox40 y ctla-4.
EA201892417A1 (ru) Антитела, распознающие тау
EA201792589A1 (ru) Антитела против cd123 и конъюгаты указанных антител
EA201692504A1 (ru) Триспецифичные связывающие молекулы и способы их применения
EA201990673A1 (ru) Антитела, специфически связывающиеся с il-17a, и их функциональные фрагменты
EA201892412A1 (ru) Антитела, распознающие тау
EA202091315A2 (ru) Антитела человека, связывающиеся с g-белком rsv
EA201792220A1 (ru) Опосредуемая антителом нейтрализация вируса чикунгунья
EA201992756A3 (ru) Антитела против cd48 и их конъюгаты
EA201990672A1 (ru) Антитела, специфически связывающиеся с pd-1, и их функциональные фрагменты
EA201890078A1 (ru) Антитело
PH12021550361A1 (en) Anti-avb8 antibodies and compositions and uses thereof
EA201991879A1 (ru) Варианты полипептидов и их применение
MX2019011585A (es) Anticuerpos miltiespecificos estables.
EA201791691A1 (ru) ОДНОДОМЕННЫЕ АНТИТЕЛА, НАПРАВЛЕННЫЕ НА CD1d
EA202090617A1 (ru) Варианты антител
CY1124244T1 (el) Παραλλαγματα αντισωματος